Goldman Sachs analyst Fulvio Cazzol upgraded Novozymes to Neutral while lowering his price target for the shares to DKK 279 from DKK 300. The analyst believes the company’s risk/reward is more balanced following its 2019 organic growth guidance of 3%-6%. He says expectations have been rebased.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.